(Q36882688)

16 August 2017

Modelling prognostic factors in advanced pancreatic cancer (English)

1 reference

16 August 2017

1 reference

D D Stocken

1

1 reference

16 August 2017

A B Hassan

2

1 reference

16 August 2017

D G Altman

3

1 reference

16 August 2017

L J Billingham

4

1 reference

16 August 2017

S R Bramhall

5

1 reference

16 August 2017

P J Johnson

6

1 reference

16 August 2017

N Freemantle

7

1 reference

16 August 2017

language of work or name

English

0 references

publication date

1 September 2008

1 reference

British Journal of Cancer

16 August 2017

1 reference

16 August 2017

99

1 reference

16 August 2017

6

1 reference

16 August 2017

883-893

1 reference

https://scigraph.springernature.com/pub.10.1038/sj.bjc.6604568

16 August 2017

0 references

cites work

An approach to estimating prognosis using fractional polynomials in metastatic renal carcinoma

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2538756

The cost of dichotomising continuous variables

29 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2538756

REporting recommendations for tumour MARKer prognostic studies (REMARK)

29 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2538756

Current standards of surgery for pancreatic cancer.

29 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2538756

Prognostic value of CA 19-9 levels in patients with inoperable adenocarcinoma of the pancreas treated with gemcitabine

29 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2538756

Phase III study of gemcitabine in combination with fluorouracil versus gemcitabine alone in patients with advanced pancreatic carcinoma: Eastern Cooperative Oncology Group Trial E2297.

29 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2538756

A double-blind placebo-controlled, randomised study comparing gemcitabine and marimastat with gemcitabine and placebo as first line therapy in patients with advanced pancreatic cancer

29 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2538756

Survival benefits of adjuvant chemotherapy with oral doxifluridine (5'-DFUR) following radiotherapy in patients with unresectable pancreatic cancer

29 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2538756

Cancer burden in the year 2000. The global picture

29 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2538756

Prognostic factors in patients with locally advanced pancreatic carcinoma receiving chemoradiotherapy

29 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2538756

Prognostic factors in patients with metastatic pancreatic adenocarcinoma receiving systemic chemotherapy

29 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2538756

Decrease of CA 19-9 during chemotherapy with gemcitabine predicts survival time in patients with advanced pancreatic cancer

29 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2538756

Modelling the effects of standard prognostic factors in node-positive breast cancer. German Breast Cancer Study Group (GBSG)

29 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2538756

An investigational new drug treatment program for patients with gemcitabine: results for over 3000 patients with pancreatic carcinoma

29 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2538756

Methodological challenges in the evaluation of prognostic factors in breast cancer

29 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2538756

Prognostic factors in patients with advanced pancreatic cancer treated with systemic chemotherapy.

29 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2538756

Multivariable prognostic models: issues in developing models, evaluating assumptions and adequacy, and measuring and reducing errors

29 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2538756

29 September 2017

Cancer statistics, 2003.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2538756

Relationship between hospital volume and late survival after pancreaticoduodenectomy.

27 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2538756

Bioelectrical impedance phase angle as a prognostic indicator in advanced pancreatic cancer

27 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2538756

Surgical treatment of pancreatic adenocarcinoma; actual survival and prognostic factors in 343 patients

4 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2538756

Prognostic factors in the operative and palliative treatment of pancreatic cancer.

4 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2538756

Are serial CA 19-9 kinetics helpful in predicting survival in patients with advanced or metastatic pancreatic cancer treated with gemcitabine and cisplatin?

4 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2538756

Predictive value of carbohydrate antigen 19-9 in pancreatic cancer treated with radiochemotherapy

4 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2538756

Prognostic factors in the palliation of pancreatic cancer

4 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2538756

Pretreatment CA 19-9 level as a prognostic factor in patients with advanced pancreatic cancer treated with gemcitabine

4 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2538756

Predicting factors for survival of patients with unresectable pancreatic cancer: a management guideline.

4 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2538756

Influence of specialization on the management and outcome of patients with pancreatic cancer.

4 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2538756

A randomised trial comparing 5-FU with 5-FU plus cisplatin in advanced pancreatic carcinoma.

4 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2538756

Multicenter randomized phase III trial comparing protracted venous infusion (PVI) fluorouracil (5-FU) with PVI 5-FU plus mitomycin in inoperable pancreatic cancer

4 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2538756

Prognostic factors in pancreatic carcinoma: serum LDH levels predict survival in metastatic disease

4 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2538756

Marimastat as first-line therapy for patients with unresectable pancreatic cancer: a randomized trial

4 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2538756

Prognostic parameters determining survival in pancreatic carcinoma and, in particular, after palliative treatment

4 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2538756

Randomized, dose-finding phase III study of lithium gamolenate in patients with advanced pancreatic adenocarcinoma.

4 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2538756

Pancreatic cancer: a report of treatment and survival trends for 100,313 patients diagnosed from 1985-1995, using the National Cancer Database.

4 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2538756

Risk factors for pancreatic cancer: an exploratory study

4 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2538756

Prognostic values of preoperative and postoperative CEA and CA19.9 levels in pancreatic cancer

4 September 2018

1 reference

12 December 2020

Treatment and survival in 13560 patients with pancreatic cancer, and incidence of the disease, in the West Midlands: An epidemiological study

1 reference

12 December 2020

Acute-phase protein response and survival duration of patients with pancreatic cancer

1 reference

12 December 2020

Prognostic significance of serum CA 242 in pancreatic cancer. A comparison with CA 19-9

1 reference

12 December 2020

Serum vascular endothelial growth factor levels in pancreatic cancer patients correlate with advanced and metastatic disease and poor prognosis

1 reference

12 December 2020

Prognostic value of dietary intake and inflammation on survival in patients with advanced cancer: relationship with performance status, pain, and digestive disorders

1 reference

12 December 2020

Intra-Arterial Infusion Chemotherapy With Angiotensin-II for Locally Advanced and Nonresectable Pancreatic Adenocarcinoma: Further Evaluation and Prognostic Implications

1 reference

12 December 2020

Pooling of Prognostic Studies in Cancer of the Pancreatic Head and Periampullary Region: the Triple-P Study

1 reference

12 December 2020

[Prognostic factors in advanced pancreatic cancer. Multivariate analysis of predictive survival score. University Surgery Association]

1 reference

12 December 2020

High-dose intraoperative radiotherapy for unresectable pancreatic cancer

1 reference

12 December 2020

A phase II trial of gemcitabine in patients with 5-FU-refractory pancreas cancer

1 reference

12 December 2020

Low mortality following resection for pancreatic and periampullary tumours in 1026 patients: UK survey of specialist pancreatic units. UK Pancreatic Cancer Group

1 reference

12 December 2020

Prognostic factors in nonresectable pancreatic adenocarcinoma: a rationale to design therapeutic trials

1 reference

12 December 2020

The clinical value of serum CEA, CA19-9, and CA242 in the diagnosis and prognosis of pancreatic cancer

1 reference

12 December 2020

Dichotomizing continuous predictors in multiple regression: a bad idea

1 reference

12 December 2020

Onset symptoms and tumor locations as prognostic factors of pancreatic cancer

1 reference

12 December 2020

Identifiers

DOI

10.1038/SJ.BJC.6604568

1 reference

Dimensions Publication ID

16 August 2017

0 references

1 reference

16 August 2017

PubMed publication ID

19238630

1 reference